Conavi Medical Applauds New Intracoronary Guidelines Validating Hybrid Imaging

Conavi Medical ( (TSE:CNVI) ) just unveiled an update.

Conavi Medical has responded positively to new intracoronary imaging guidelines issued by major medical organizations, which emphasize the critical roles of IVUS and OCT in coronary procedures. These guidelines, rated at the highest level of evidence, validate Conavi’s Novasight system as the only hybrid IVUS-OCT device, enhancing its market position by supporting improved patient outcomes and streamlined procedures.

More about Conavi Medical

Conavi Medical is a commercial stage medical device company specializing in the design, manufacture, and marketing of imaging technologies for minimally invasive cardiovascular procedures. Its flagship product, the Novasight Hybrid System, uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries, and has received regulatory approvals in the U.S., Canada, China, and Japan.

YTD Price Performance: 15.56%

Average Trading Volume: 5,403

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $8.49M

Learn more about CNVI stock on TipRanks’ Stock Analysis page.